Effect of hepatic and renal impairment on the pharmacokinetics of olanzapine and samidorphan given in combination as a bilayer tablet
Lei Sun,1 Sergey Yagoda,2 Yangchun Du,3 Lisa von Moltke21Department of Clinical Pharmacology and Translational Medicine, Alkermes, Inc., Waltham, MA, USA; 2Department of Clinical Research, Alkermes, Inc., Waltham, MA, USA; 3Department of Biostatistics, Alkermes, Inc., Waltham, MA, USACorrespondence:...
Main Authors: | Sun L, Yagoda S, Du Y, von Moltke L |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2019-08-01
|
Series: | Drug Design, Development and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/effect-of-hepatic-and-renal-impairment-on-the-pharmacokinetics-of-olan-peer-reviewed-article-DDDT |
Similar Items
-
A validated RP-UPLC method for estimation of Samidorphan and Olanzapine in mixed powder and combined tablets
by: Krishnaphanisri Ponnekanti, et al.
Published: (2023-11-01) -
Bioanalytical method development and validation for the simultaneous estimation of Olanzapine and Samidorphan in rabbit plasma by using HPLC–MS/MS and application to pharmacokinetic study
by: Rambabu Kantipudi, et al.
Published: (2024-01-01) -
Effects of Combined Therapy of Olanzapine and Samidorphan on Safety and Metabolic Parameters in Schizophrenia Patients: A Meta-Analysis
by: Peng Z, et al.
Published: (2023-10-01) -
Novel Compounds in the Treatment of Schizophrenia—A Selective Review
by: Evangelia Maria Tsapakis, et al.
Published: (2023-08-01) -
A Phase 1, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics of Iberdomide in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared with Healthy Subjects
by: Cheng Y, et al.
Published: (2023-02-01)